Luigia Carapezza

❤️Felice di condividere la notizia: secondi classificati nella sfida tra le reti oncologiche 💪❤️🥈Direzione scientifica, @AdamoVadamo, coordinatore rete oncologica Sicilia; Gianni Amunni, coordinatore rete oncologica Toscana 👇 palermo.gds.it/video/salute/2…

It is an big honor to share another work of the ARON group. Fantastic collaboration. Huge team! @EurUrolOncol @DrIacovelli @drenriquegrande @CPRT65 @procopio_g @SoaresAndrey @DrIgnacioOrtego @fsabino_onco @vmollica7

📍Supporto psico-oncologico on-line per persone con diagnosi oncologica in qualsiasi fase della malattia. 📍Le consulenze sono rivolte anche ai caregivers. Per ulteriori informazioni e prenotazioni 📩 luigiacarapezza@gmail.com

@RebeccaDeFiore @RasoiniR @oncoblogger @docNSC @Dottor_T @camialderighi @AleDimitrio @SilCastelletti @AntonioClavenna @darioT_ @eugeniosantoro @IoanaA_Cristea Fatto!

Chiedo alle amiche e agli amici di Twitter di rispondere alla survey di Forward su ChatGPT e di aiutarci a farla girare 👇🏼 @RasoiniR @oncoblogger @psico_onco @docNSC @Dottor_T @camialderighi @AleDimitrio @SilCastelletti @AntonioClavenna @darioT_ @eugeniosantoro @IoanaA_Cristea

Lo studio di fase III THOR ha dimostrato una riduzione del rischio di morte del 36% #ASCO23 @GustaveRoussy #oncology oncoinfo.it/congressi/erda…

Phenomenal job by @shilpaonc presenting phenomenal data for the combination of #endortumab #pembrolizumab in cis-ineligible #bladdercancer. Amazing to see data holding with 4-year follow-up! Kudos to the investigators. #ASCO23

Finally the day has arrived: looking forward to our #ASCO23 educational session on managing the toxicity of estrogen deprivation therapy in patients with #BreastCancer…really honored and grateful to be part of it! @OncoAlert @ASCO @UniGenova @SanMartino_Ge #UNIGEnonsiferma

Subset analysis of THOR (erdaftinib vs chemo in FGFR+ve UC) showed ⬆️ benefit for upper tract disease, suggesting other biology beyond FGFR predict response. Multiple methods have been used for FGFR expression. We’ve not perfected this biomarker (as with PD-L1) #ASCO2023

Today, our patients with metastatic #urothelialcancer have another option for treatmt. Molecularly selected pts by FGFR3/2 gene alt have the opportunity to receive a driven TKI. Congrats for this achievement at THOR trial & thanks to @y_loriot for such a brilliant talk #ASCO23

I am excited about the plenary session starting in a few minutes ⁦@YaleCancer⁩ ⁦@ASCO⁩. I will be presenting the overall survival data from the ADAURA study ⁦for early stage EGFR mutant lung cancer. more soon…⁦@ASCOPres⁩

🚨🔥@OncoAlert Hot off the press. Just published @NEJM, in conjunction with presentation @ASCO #ASCO23 plenary session by @DrRoyHerbstYale & team. #OverallSurvival Results of #ADAURA Trial: “Adjuvant #Osimertinib in resected #EGFR‑mutant #NSCLC” 👇🏼 nejm.org/doi/full/10.10…

The addition of Talazoparib(PARPi) to enza in CRPC has most effect in BRCA+ve tumors. Effects in the remaining HRR population are marginal or -ve (e.g. ATM). This is largely consistent with previous data for PARPi in CRPC, supporting the ODAC decision on olaparib #ASCO2023

This just in at #ASCO23: positive results from our ADAURA Phase III trial for a particular set of patients with #NSCLC. Read more about the new data: bit.ly/3N7Bo7f

A key take a way message from #ASCO23: ARTIFICIAL INTELLIGENCE is just around the corner to be used in daily practice to choose pts treatmt in #ProstateCancer Amazing presentation & work from @AarmstrongDuke & cols. @EstudioDipcan @OncoAlert @urotoday @MDAnderson_ES @genomcore

Q-TWIST analysis looks at time without grade 3/4 adverse events, progression or death. It indication (with shortcoming) quality time without PD (area in pink on the graphs). Avelumab outperforms BSC: longer PFS and OK tox. Huge amount of work from Paul Cislo at Pfizer. #ASCO2023

@rleonferre @OncoAlert 😄😂

The feeling this year. Have to split my stay in two different hotels because Taylor Swift fans and cancer researchers and clinicians are competing for rooms in Chicago! @OncoAlert #ASCO23

Grande @DottorClaudio 👏 il primo italiano della storia in una sessione educazionale al congresso #ASCO2023 📢"No patient left behind" 💪❤️

👏🙏🤍

#ASCO23 | Fantastic visionary talk by Dr Monica M. Bertagnolli MD @NCIDirector at @ASCO on some of the important goals for our patients & families for future of innovative clinical trials research 🙌 #Leadership #CancerResearch

#ASCO2023 #lungcancer 👇

@crisbergerot @ASCO @tompowles1 @montypal @PauloBergerot @DrChoueiri @spsutkaMD @AlbigesL @ERPlimackMD @brian_rini @virajmaster @DrTHut @ViktorGruenwald 👏💪

Excited to present our poster at #ASCO23 @ASCO! Visit Poster Board 32 to learn about our study on the perceived relevance of questions in FKSI-19, EORTC QLQ-C30, & EQ-5D Interesting findings reveal that only a few items were deemed relevant by our pts w RCC @tompowles1 @montypal